Journal of the American Heart Association · 12 Nov 2026
Side Effects of Low‐Dose Colchicine in Chronic Coronary Disease: A Post Hoc Analysis of the LoDoCo2 Trial
Jalina Jannink, Jenny van der Veen, Niekbachsh Mohammadnia, Marte F. van der Bijl, Eric Boersma, Amber van Broekhoven, Charley A. Budgeon, Jan H. Cornel, John W. Eikelboom, Saloua El Messaoudi, Stefan M. Nidorf, Tjerk S. J. Opstal, Jeanine E. Roeters van Lennep, Hester M. den Ruijter, Astrid Schut, Jan Tijssen, Fabrice M. A. C. Martens, Frank L. J. Visseren, Arend Mosterd, Aernoud T. L. Fioleth-index 4
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Background Low‐dose colchicine reduces cardiovascular events in patients with chronic coronary disease. However, side effects may compromise compliance and lead to discontinuation of treatment. Therefore, we aimed to assess the incidence of side effects leading to discontinuation of treatment in the LoDoCo2 (Low‐Dose Colchicine 2) trial. Methods The LoDoCo2 trial was a randomized controlled trial evaluating colchicine versus placebo in patients with chronic coronary disease. Participants entered a 30‐day open‐label run‐in phase during which all participants received colchicine 0.5 mg once daily, followed by randomization to colchicine or placebo. Tolerability‐related side effects leading to treatment discontinuation were evaluated at the end of the 30‐day run‐in phase and during the randomized phase (median follow‐up, 29.5 [interquartile range, 21.6–47.4] months). Cumulative incidence of side effects was presented using Kaplan–Meier curves and compared by treatment arm using Cox proportional hazards models. Results During the 30‐day run‐in phase, 618 of 6519 (9.5%) participants reported side effects. Women had a higher risk of side effects than men during the 30‐day run‐in phase (odds ratio, 1.53 [95% CI, 1.23–1.89]). After randomization, 114 participants (4.2%) in the colchicine group and 120 (4.4%) in the placebo group discontinued treatment due to side effects (hazard ratio [HR], 0.95 [95% CI, 0.73–1.22]). Gastrointestinal symptoms were most common (colchicine 2.0% versus placebo 1.7%) followed by myalgia (colchicine 1.2% versus placebo 1.6%). No differences in the risk of side effects between colchicine and placebo were seen for any of the subgroups. Women did have a higher risk of reporting side effects compared with men, regardless of assigned treatment (HR, 1.66 [95% CI, 1.22–2.25]). Conclusions In patients with chronic coronary disease that tolerated initial treatment with low‐dose colchicine, long‐term discontinuation due to side effects was uncommon and did not differ between colchicine and placebo. Registration URL: https://www.anzctr.org/au ; Unique identifier: ACTRN12614000093684.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Aernoud T. L. Fiolet has the highest h-index among the authors (4).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (37)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 17 more references
A free account opens the rest of the citing papers and references on every paper’s page.